ANT-GROUP
5.3.2024 12:28:33 CET | Business Wire | Press release
For the third consecutive year, Ant Group, a global digital technology provider, has been recognized as a Top 100 Global Innovator™ 2024 by Clarivate™, a global leader in connecting people and organizations to intelligence they can trust to transform their world. This recognition reaffirms Ant Group's ongoing commitment to innovation excellence in technologies such as artificial intelligence (AI) and blockchain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305020027/en/
Clarivate recognizes Ant Group as one of the Top 100 Global Innovators 2024 (Graphic: Business Wire)
Gordon Samson, President, Intellectual Property, Clarivate, said, “We congratulate Ant Group for being named as a Top 100 Global Innovator again. To feature as a Top 100 Global Innovator is no mean feat as maintaining an edge in the innovation ecosystem is harder than ever. Organizations must balance experimentation and risk with discipline and reward. We measure and rank innovative performance in a dynamic and thorough way, using live thresholds of differentiation. At Clarivate, we think forward by analyzing the quality of ideas, their potency and their impact to identify the world’s top innovators, and this year we reveal the ranking of these innovators for the first time.”
As of the end of 2023, Ant Group had filed 32,459 patent applications globally, with 22,102 patents granted. The top three categories of these patent applications are security technology, blockchain and AI.
"Our recognition by Clarivate as one of the Top 100 Global Innovators is a testament to our innovation capabilities," said Shen PAN, Director of Patents at Ant Group. "We are committed to leveraging technology to build trust and accelerate digital transformation across industries. Our journey is driven by our advancements in key technologies such as blockchain, privacy computing, security technology, Internet of Things (IoT) databases, and most notably, AI.”
In the field of AI, Ant Group has been continuously leveraging its technology to enhance the user experience across its product offerings for years. As of the end of 2023, Ant Group had filed over 3,000 AI-related patents. During Alipay’s 2024 Chinese New Year campaign, AI features in the app attracted 600 million interactions.
To facilitate technological advancement across industries, Ant Group has been making its innovations publicly accessible to developers in the open-source community. For example, Ant Group’s AI infrastructure team open-sourced ATorch, an extension library of PyTorch, that can improve GPU utilization rate up to 60% in large-scale pre-trainings of Large Language Models (LLMs). Meanwhile, the company’s open-sourced Lookahead achieves lossless generation accuracy for LLMs while boosting the inference speeds of LLMs by 2 to 6 times.
By the end of 2023, the number of open-source repositories from Ant Group on platforms such as GitHub had exceeded 1,900. Additionally, according to the 2023 Blue Paper on the Development of Open Source in China published by China OSS Promotion Union (COPU), Ant Group is recognized as one of the top three organizations in the country in terms of open-source contributions and influence.
Leveraging its innovations in technologies such as blockchain, privacy computing, security technology, IoT, and databases, Ant Group provides technology products and services to support the digital transformation and collaboration of global enterprise customers across a variety of industries. These industries include banking, telecommunication, real estate, medicine and energy. The company has garnered recognition from various organizations for its excellence in delivering innovative products and services to customers. For example, AntChain was recognized by Forbes on the Blockchain 50 list for five consecutive years (from 2019 to 2023). In September 2023, ZOLOZ was named as a Representative Vendor for the second consecutive time in the latest Gartner Market Guide for Identity Verification.
Methodology
The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power.
To move from the individual idea strength to identify the organizations that create them more consistently and frequently, Clarivate sets two threshold criteria that potential candidates must meet and then adds a measure of their patented innovation output over the past five years.
For full information on the methodology used to identify the 2024 list, see here.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
About Ant Group
Ant Group traces its roots back to Alipay, which was established in 2004 to create trust between online sellers and buyers. Over the years, Ant Group has grown to become one of the world's leading open Internet platforms.
Through technological innovation, Ant Group supports its partners in providing inclusive, convenient digital life and digital financial services to consumers and SMEs. In addition, it has been introducing new technologies and products to support the digital transformation of industries and facilitate industrial collaboration. Working together with global partners, the company enables merchants and consumers to make and receive payments and remit around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305020027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom